Physician profile
Joanne Chang
NPI 1336312271
$3,095.46
in general payments reported to CMS, 2019-2025
34 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $617 · 2021: $674 · 2022: $638 · 2023: $430 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $546.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $568.13 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Bayer Healthcare Pharmaceuticals INC. | $361.92 | 2019-2023 | |
| Daiichi Sankyo INC. | $177.29 | 2020-2023 | Injectafer |
| Medtronic, INC. | $174.68 | 2021-2023 | Truclear |
| Therapeuticsmd, INC. | $161.37 | 2019-2022 | |
| Evofem Biosciences, INC. | $149.83 | 2020-2023 | Phexxi |
| Mayne Pharma Commercial LLC | $140.57 | 2021-2022 | |
| Hologic Sales and Service, LLC | $136.30 | 2019-2025 | Acessa Provu System, Novasure |
| Radius Health, INC. | $133.47 | 2019-2023 | |
| Organon LLC | $130.20 | 2022-2025 | Nexplanon |
| Lupin INC. | $91.97 | 2019-2020 | |
| Exeltis, USA INC. | $88.24 | 2019-2023 | Slynd |
| Astellas Pharma US INC | $83.25 | 2019-2023 | Veozah, Myrbetriq |
| Vertical Pharmaceuticals, LLC | $71.16 | 2019 | |
| Smith+Nephew, INC. | $66.00 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $57.48 | 2019-2021 | |
| Amgen INC. | $55.32 | 2019-2023 | Prolia, Evenity |
| Allergan, INC. | $51.48 | 2019 | |
| Agile Therapeutics, INC. | $49.87 | 2021-2022 | |
| Pfizer INC. | $48.19 | 2021-2023 | |
| Myovant Sciences INC. | $43.43 | 2021-2022 | |
| Coopersurgical, INC. | $38.48 | 2021-2023 | Paragard T 380a |
| Merck Sharp & Dohme LLC | $28.94 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $27.19 | 2019-2020 | |
| Davol INC. | $20.77 | 2020 | |
| Sumitomo Pharma America, INC. | $20.54 | 2023 | Myfembree |
| Duchesnay USA Incorporated | $20.46 | 2019 | |
| Exact Sciences Corporation | $18.85 | 2023 | Cologuard Collection Kit |
| Mylan Pharmaceuticals INC. | $15.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.91 | 2022 | |
| Medicem INC. | $13.82 | 2020 | |
| Scynexis, INC. | $13.75 | 2021 | |
| Millicent US INC | $12.46 | 2019 | |
| Dysis Medical, INC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanne Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.